Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] jumped around 0.15 points on Wednesday, while shares priced at $1.07 at the close of the session, up 16.74%.
Lexicon Pharmaceuticals Inc stock is now -35.54% down from its year-to-date (YTD) trading value. LXRX Stock saw the intraday high of $1.08 and lowest of $0.9078 per share. The company’s 52-week high price is 2.45, which means current price is +282.14% above from all time high which was touched on 01/24/25.
Compared to the average trading volume of 5.04M shares, LXRX reached a trading volume of 7673552 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Lexicon Pharmaceuticals Inc [LXRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $2.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on March 05, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 17, 2024, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $5, while Leerink Partners analysts kept a Outperform rating on LXRX stock.
The Price to Book ratio for the last quarter was 3.16, with the Price to Cash per share for the same quarter was set at 0.54.
How has LXRX stock performed recently?
Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.03. With this latest performance, LXRX shares gained by 39.56% in over the last four-week period, additionally plugging by 35.68% over the last 6 months – not to mention a rise of 44.89% in the past year of trading.
Lexicon Pharmaceuticals Inc [LXRX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Lexicon Pharmaceuticals Inc [LXRX] shares currently have an operating margin of -540.04% and a Gross Margin at 96.22%. Lexicon Pharmaceuticals Inc’s Net Margin is presently recorded at -568.04%.
Return on Equity for this stock declined to -49.60%, with Return on Assets sitting at -49.60%.
Earnings analysis for Lexicon Pharmaceuticals Inc [LXRX]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lexicon Pharmaceuticals Inc go to 30.30%.
Insider trade positions for Lexicon Pharmaceuticals Inc [LXRX]
There are presently around $74.93%, or 75.82% of LXRX stock, in the hands of institutional investors. The top three institutional holders of LXRX stocks are: ARTAL GROUP S.A. with ownership of 175.1 million shares, which is approximately 56.3318%. FMR LLC, holding 38.69 million shares of the stock with an approximate value of $$64.99 million in LXRX stocks shares; and FMR LLC, currently with $$16.62 million in LXRX stock with ownership which is approximately 3.1818%.
